Keywords: ligand, full-year, loss, improves, usa, pharmaceuticals, says
Ligand's full-year 2005 loss improves 19%
Article | 27 March 2006
The USA's Ligand Pharmaceuticals says that, according to its unaudited preliminary results, net loss for the year ended December 31, 2005, was $36.4 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
